GLPG Galapagos NV

Galapagos Receives Transparency Notification from Bank of America

Galapagos Receives Transparency Notification from Bank of America

Mechelen, Belgium; February 16, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Bank of America.

Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on February 11, 2026, from Bank of America Corporation. The notification indicates that Bank of America Corporation, as controlling entity, crossed above the threshold of 5% of Galapagos’ voting rights on February 9, 2026, including the threshold of 5% for equivalent financial instruments was exceeded, as a result of an acquisition of Galapagos’ voting rights and equivalent financial instruments.

On February 11, 2026, the Bank of America Corporation (taking into account the holding of its affiliates) owned 104,522 voting rights and 3,415,894 equivalent financial instruments, representing together 5.34% of Galapagos’ currently outstanding 65,897,071 shares.

Summary of the transaction:

Date on which the threshold was crossedDate of notificationDirect voting rights after the transactionEquivalent financial instruments after the transactionTotal (%)

voting rights
February 9, 2026February 11, 20260.16%5.18%5.34%

Content of the notifications from Bank of America Corporation:

The notification dated February 11, 2026, contains the following information:

  • Date of notification: February 11, 2026
  • Date on which the threshold is crossed: February 9, 2026
  • Threshold of voting rights crossed (in %): 5%
  • Notification by: Bank of America Corporation
  • Denominator: 65,897,071
  • Reason for the notification: Acquisition or disposal of financial instruments that are treated as voting securities
  • Notified details:



A) Voting RightsPrevious notificationAfter the transaction
 # of voting rights# of voting rights% of voting rights
Holder of voting rights Linked to securitiesNot linked to securitiesLinked to securitiesNot linked to securities
Bank of America Corporation00 0.00% 
Bank of America, National Association12,47512,481 0.02% 
Merrill Lynch International105,02677,455 0.12% 
Managed Account Advisors LLC33 0.00% 
BofA Securities, Inc.00 0.00% 
Merrill Lynch, Pierce, Fenner & Smith

Incorporated
14,46214,462 0.02% 
U.S. Trust Company of Delaware121121 0.00% 
Subtotal132,087104,522 0.16% 
 TOTAL104,52200.16%0.00%



B) Equivalent financial instrumentsAfter the transaction
Holder of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
Merrill Lynch InternationalRight to Recall  149,6800.23%physical
BofA Securities, Inc.Right to Recall  29,4000.04%physical
BofA Securities, Inc.Rights of Use  3,013,8904.57%physical
Merrill Lynch InternationalRights of Use  1,2750.00%physical
Bank of America, National AssociationPhysical Call Option19/06/2026 100,0000.15%physical
Bank of America, National AssociationSwaps15/06/2026 12,5000.02%cash
Bank of America, National AssociationSwaps15/01/2027 4,2160.01%cash
Bank of America, National AssociationSwaps15/10/2027 150.00%cash
Bank of America, National AssociationSwaps31/01/2028 6510.00%cash
Bank of America, National AssociationSwaps09/03/2026 29,0700.04%cash
Merrill Lynch InternationalSwaps15/06/2026 12,5000.02%cash
Merrill Lynch InternationalSwaps15/01/2027 15,4050.02%cash
Merrill Lynch InternationalSwaps15/10/2027 150.00%cash
Merrill Lynch InternationalSwaps30/04/2026 11,0000.02%cash
Merrill Lynch InternationalSwaps02/07/2026 1,2500.00%cash
Merrill Lynch InternationalSwaps01/11/2027 5,2300.01%cash
Merrill Lynch InternationalSwaps29/01/2027 4150.00%cash
Merrill Lynch InternationalSwaps27/02/2026 3120.00%cash
Merrill Lynch InternationalSwaps09/03/2026 29,0700.04%cash
 TOTAL  3,415,8945.18% 



TOTAL (A&B)# of voting rights% of voting rights
 3,520,4165.34%

The chain of control has been described at the end of the notification (section 11) and can be found .

For further information, contact Galapagos:

Investor Relations

Glenn Schulman



Media

Media

Katie Morris



Visit us at or follow us on or .


1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions, as amended from time to time.

Attachment



EN
16/02/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galapagos NV

Jacob Mekhael
  • Jacob Mekhael

Galapagos Signs agreement with Gilead on T-cell Engager in autoimmune ...

Galapagos announced that, following Gilead entering into a definitive agreement to acquire Ouro Medicines for $1,675m in cash consideration, and up to $500m in contingent milestone payments, Galapagos and Gilead have now entered into a binding agreement to collaborate on advancing gamgertamig (BCMAxCD3 T cell engager) in autoimmune diseases. This agreement comes after the companies announced their advanced discussions on the collaboration last week. Economically, Galapagos is effectively co-fina...

Guy Sips ... (+4)
  • Guy Sips
  • Jacob Mekhael
  • Mathijs Geerts Danau
  • Wim Lewi
 PRESS RELEASE

Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerkin...

Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder te ontwikkelen De nieuwe samenwerkingsstructuur levert aanzienlijk verbeterde financiële voorwaarden en flexibiliteit voor Galapagos op  Na deze transactie blijft de Vennootschap over het grootste deel van haar liquide middelen beschikken voor bijkomende strategische transacties en andere prioriteiten van kapitaalallocatie Kans om met gamgertamig een potentieel first-in-class & best-in-class T-cell-engager in auto-immuunziekten te ontwikkelen ...

 PRESS RELEASE

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Ad...

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos  Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities Opportunity to develop a potential first-in-class & best-in-class T cell engager in autoimmune diseases with gamgertamig Management to host conference call today, March 31, 20...

 PRESS RELEASE

Galapagos kondigt de voordracht aan van Gino Santini tot lid van de Ra...

Galapagos kondigt de voordracht aan van Gino Santini tot lid van de Raad van Bestuur De Raad van Bestuur is voornemens de heer Santini te benoemen tot Voorzitter, als opvolger van Jérôme Contamine, onder voorbehoud van zijn benoeming door aandeelhouders De heer Santini zal uitgebreide ervaring op het gebied van corporate governance, bedrijfsontwikkeling en leiderschap in de sector toevoegen aan de Raad van Bestuur Mechelen, België; 26 maart, 2026, 21:02 CET — Galapagos NV (Euronext & NASDAQ: GLPG), heeft vandaag bekendgemaakt dat Gino Santini is voorgedragen als Niet-Uitvoerend Onafhankel...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch